Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (215)

81

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

enthalten in: Leukemia | 2021

von Casneuf, T. | Adams, H. | van de Donk, N. | +20

82

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

enthalten in: Advances in therapy | 2021

von Chari, A. | Munder, M. | Weisel, K. | +18

83

First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands : a population-based study, 1989-2018

enthalten in: Blood cancer journal | 2021

von Brink, M. | Visser, O. | Zweegman, S. | +4

84

Multiple myeloma

enthalten in: Lancet (London, England) | 2021

von van de Donk, N. | Pawlyn, C. | Yong, K.

85

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma

enthalten in: International journal of molecular sciences | 2021

von Poels, R. | Drent, E. | Lameris, R. | +6

86

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

enthalten in: Advances in therapy | 2021

von Chari, A. | Munder, M. | Weisel, K. | +18

87

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

enthalten in: Advances in therapy | 2021

von Chari, A. | Munder, M. | Weisel, K. | +18

88

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

enthalten in: Advances in therapy | 2021

von Chari, A. | Munder, M. | Weisel, K. | +18

89

Expert review on soft‐tissue plasmacytomas in multiple myeloma : definition, disease assessment and treatment considerations

enthalten in: British Journal of Haematology | 2021

von Rosiñol, L. | Beksac, M. | Zamagni, E. | +35

90

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies

enthalten in: Cancers | 2020

von Verkleij, C. | Jhatakia, A. | Broekmans, M. | +5